Ceftriaxone is under clinical development by scPharmaceuticals and currently in Phase III for Gram-Positive Bacterial Infections. According to GlobalData, Phase III drugs for Gram-Positive Bacterial Infections have a 43% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Ceftriaxone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ceftriaxone is under development for the treatment of infections caused by gram-positive and gram-negative bacteria. The drug candidate is administered by the subcutaneous route and intravenous route. Ceftriaxone is a beta-lactam compound in which the beta-lactam ring is fused to a 6-membered dihydrothiazine ring. It is delivered using micropump. It acts by targeting penicillin-binding protein (PBP).
scPharmaceuticals is a clinical-stage pharmaceutical company. The company’s pipeline products include subcutaneous formulations of furosemide, ceftriaxone, and carbapenem. Its furosemide formulation is a loop diuretic widely used in prescription pharmaceuticals for the management of edema in patients with decompensated heart failure due to the highly variable and overall reduction in the bioavailability of oral formulations. scPharmaceuticals’ Ceftriaxone is an antibiotic used intravenously for the treatment of infections caused by gram-positive and gram-negative organisms. The company’s carbapenems are antibotics used intravenously for the treatment of infections caused by gram-negative organisms. It also provides clinical trial services. scPharmaceuticals is headquartered in Burlington, Massachusetts, the US..
For a complete picture of Ceftriaxone’s drug-specific PTSR and LoA scores, buy the report here.